Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 1999

View Archived Issues

Company Profile: Axonyx

Nutropin Depot looks promising in phase III GHD trial

Uncarinic acids with anticancer potential

Evotec BioSystems and Pfizer enter drug discovery alliance

Cantab's vaccine for cocaine addiction shows encouraging phase I results

Alexion's C5 inhibitor safe and effective in phase I lupus trial

Enrollment of ABX-IL-8 phase I/II psoriasis trial completed

Phenolic hormone inhibits smooth muscle cells in prostate tissue

Selective, efficacious chemosensitizer discovered

Celltech and Chiroscience agree to merge

Unique antiobesity therapy approved in Canada

Pfizer presents new GH secretagogue at ENDO '99

Cytogen acquires Prostagen, forms joint venture with Progenics

Labeling and use changes announced for Rezulin

GnRH antagonist A-222509: coadministration with ritonavir improves potency and PK

Tabimorelin is a potent and specific GH secretagogue in healthy volunteers

Pfizer research team selects antiobesity candidate for clinical testing

Elastase inhibitor UT-77 in active development at United Therapeutics

NIAID sponsors phase III trial of varicella vaccine for prevention of shingles

Schering-Plough launches alkylating agent in second major market

Potassium channel-modulating immunosuppressants designed at Merck

Vaccines and vaccine vectors comprising auxotrophic attenuated strains of Listeria

Humanized monoclonal antibody for diabetic complications developed at Exocell

Sankyo presents new agents with potent blood glucose-lowering activity

New class of tachykinin antagonists synthesized at MS&D, particularly useful for emesis

International patent covers new Schering-Plough antiallergic agents

Benzocycloheptenes as PGI2 agonists in early development at Fujisawa

Ono claims new series of matrix metalloproteinase inhibitors

Orally active GnRH antagonist evaluated in preclinical models by Abbott investigators

A-198401: another compound emerges from Abbott's focus on nonpeptide GnRH antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...